Mawer Investment Management Ltd. Buys 5,769 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Mawer Investment Management Ltd. lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 14.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,629 shares of the medical research company’s stock after purchasing an additional 5,769 shares during the period. Mawer Investment Management Ltd. owned about 0.09% of Charles River Laboratories International worth $8,608,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allstate Corp bought a new position in shares of Charles River Laboratories International in the 4th quarter worth about $277,000. Brown Brothers Harriman & Co. increased its position in Charles River Laboratories International by 190.3% in the 4th quarter. Brown Brothers Harriman & Co. now owns 389 shares of the medical research company’s stock valued at $72,000 after buying an additional 255 shares in the last quarter. DnB Asset Management AS raised its holdings in Charles River Laboratories International by 1.4% during the fourth quarter. DnB Asset Management AS now owns 8,690 shares of the medical research company’s stock worth $1,604,000 after buying an additional 124 shares during the last quarter. Nomura Asset Management Co. Ltd. boosted its stake in Charles River Laboratories International by 0.7% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 15,694 shares of the medical research company’s stock valued at $2,897,000 after purchasing an additional 102 shares during the last quarter. Finally, New Age Alpha Advisors LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $3,429,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

CRL stock opened at $155.60 on Friday. The firm has a market cap of $7.96 billion, a price-to-earnings ratio of 1,037.35, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $273.32. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The business’s fifty day simple moving average is $164.69 and its two-hundred day simple moving average is $182.68.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.46 EPS. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Activity

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on CRL. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a research report on Monday, March 3rd. Barclays cut their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday, February 18th. Bank of America cut their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Robert W. Baird reduced their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).